Taysha Gene Therapies Statistics
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
3.72-0.05 (-1.33%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies by the numbers
Taysha Gene Therapies has a market capitalization of $1.21 billion based on 326.05M shares outstanding. With trailing EPS of $-0.42, Taysha Gene Therapies is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 14.5% below its 50-day average and 29.6% below its 200-day average.
Average daily trading volume is 3.59M shares, or about $13.4 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
TSHA valuation vs. peer median
| Metric | TSHA | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.21B | $1.39B | -13% |
| Avg. volume | 3.59M | 698.28K | +414% |
Peer median across 8 companies: NVAX, VOR, IMCR, MESO, INBX, WWB, ALVO, RXRX.
Valuation
- Market cap
- $1.21B
- Price / sales (latest FY)
- 124.11
- EPS (TTM)
- $-0.42
- Shares outstanding
- 326.05M
Price and trading
- Previous close
- 3.77
- Open
- 3.67
- Day range
- 3.60 – 3.80
- 52-week range
- 3.46 – 7.30
- 52-week change
- -11.22%
- Beta
- —
- Volume
- 3.15M
- Average volume
- 3.59M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 12, 2026
Additional statistics
- Market Cap
- 1.21B
- Forward Pe
- -9.60
- Eps
- -0.42
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 7.30
- Week52 Low
- 3.46
- Avg Volume
- 3.59M
- Shares Outstanding
- 326.05M
- Ma50
- 4.35
- Ma200
- 5.28
- Earnings Date
- Nov 12, 2026
- Pct From52w High
- -49.04%
- Pct From52w Low
- 7.67%